NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%
Reuters
Aug 12
NeurAxis Inc. <a href="https://laohu8.com/S/QTWO">Q2</a> 2025: Revenues Surge 46%, Operating Loss Improves by 22%
NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.